Am J Gastroenterol 2021 May 13. Epub 2021 May 13.
Division of Hepatology, Bruce W Carter VA Medical Center, Miami, Florida, USA; Department of Medicine, Jackson Memorial Hospital, Miami, Florida, USA; Division of Digestive Health and Liver Diseases, University of Miami Miller School of Medicine, Miami, Florida, USA; Department of Health Behavior and Policy, Virginia Commonwealth University, Richmond, Virginia, USA; Division of Gastroenterology and Hepatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Division of Gastroenterology and Hepatology, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania, USA; Section of Digestive Diseases, Yale School of Medicine, New Haven, Connecticut, USA; Division of Gastroenterology and Hepatology, VA Connecticut Healthcare System, West Haven, Connecticut, USA.
Introduction: Patients with cirrhosis and men have been under-represented in most studies examining the clinical benefit of response to ursodeoxycholic acid (UDCA) in primary biliary cholangitis (PBC). The aim of this study was to study the association of UDCA response and liver-related death or transplantation, hepatic decompensation, and hepatocellular carcinoma (HCC) in patients with PBC cirrhosis.
Methods: We conducted a retrospective cohort study of veterans, predominantly men, with PBC and compensated cirrhosis to assess the association of UDCA response with the development of all-cause and liver-related mortality or transplantation, hepatic decompensation, and HCC using competing risk time-updating Cox proportional hazards models. Read More